Vontobel Holding
PTGX icon

Vontobel Holding’s Protagonist Therapeutics PTGX Stock Holding History

Vontobel Holding’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-40,000
Closed -$920K – 1137
2023
Q1 		$920K Hold
40,000
– – 0.01% 610
2022
Q4 		$436K Buy
40,000
+10,000
+33% +$84.4K ﹤0.01% 792
2022
Q3 		$253K Buy
30,000
+10,000
+50% +$94.6K ﹤0.01% 896
2022
Q2 		$158K Hold
20,000
– – ﹤0.01% 965
2022
Q1 		$474K Hold
20,000
– – ﹤0.01% 808
2021
Q4 		$684K Hold
20,000
– – 0.01% 733
2021
Q3 		$354K Buy
20,000
+10,000
+100% +$426K ﹤0.01% 899
2021
Q2 		$449K Hold
10,000
– – ﹤0.01% 798
2021
Q1 		$259K Buy
+10,000
New +$253K ﹤0.01% 854

Other funds holding PTGX

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
CAC
Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Vontobel Holding's PTGX Position: Q2 2023 in Review

Vontobel Holding sold out of Protagonist Therapeutics (PTGX) in Q2 2023, closing a stake of 40,000 shares — an estimated $920K sold.

Vontobel Holding first reported a position in PTGX in Q1 2021 and held it in 9 quarters. The position peaked at $920K in Q1 2023. 167 funds tracked by Wall St. Rank hold PTGX as of Q2 2023.

  • Vontobel Holding reported no remaining Protagonist Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Vontobel Holding sold 40,000 Protagonist Therapeutics shares in Q2 2023, an estimated $920K.
  • Vontobel Holding first reported a position in Protagonist Therapeutics in Q1 2021 and held it in 9 quarters.
  • Vontobel Holding's Protagonist Therapeutics position peaked at $920K in Q1 2023.
  • 167 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2023.

Based on Vontobel Holding's 13F filing for Q2 2023, filed 24 Jul 2023.